Browse Studies — Arctuva

Phase 4

CAST-AI: Cystectomy After Systemic Therapy With ADC and Immunotherapy

This phase IV trial tests the impact of standard of care enfortumab vedotin and pembrolizumab followed by removal of all or part of the bladder (cytoreductive …

Locally Advanced Bladder Urothelial CarcinomaLocally Advanced Renal Pelvis and Ureter Urothelial CarcinomaMetastatic Bladder Urothelial Carcinoma+4 more

Estimated

~$10 – $6,250

Mayo ClinicNCT06764095

Phase 1

A Phase Ib/II Study to Evaluate the Safety and Efficacy of Enfortumab Vedotin Plus Pembrolizumab in Combination With Quemliclustat in Unresectable Locally Advanced and Metastatic Urothelial Carcinoma

This phase Ib/II trial tests the safety, side effects, and best dose of quemliclustat in combination with enfortumab vedotin and pembrolizumab, and to see how …

Locally Advanced Bladder Urothelial CarcinomaLocally Advanced Renal Pelvis Urothelial CarcinomaLocally Advanced Ureter Urothelial Carcinoma+10 more

Estimated

~$10 – $6,250

Integrated Cancer Repository for Cancer Research

The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimen…

Pancreatic CancerThyroid CancerLung Cancer+47 more

Estimated

~$10 – $750

Phase 2

MC220503 Randomized Phase II Rescuing Cancer Immunotherapy With Plasma Exchange in Bladder Cancer 1 (ReCIPE-B1)

This phase II trial compares therapeutic plasma exchange followed by enfortumab vedotin and pembrolizumab to standard of care next-line therapy for the treatme…

Metastatic Bladder Urothelial CarcinomaMetastatic Renal Pelvis and Ureter Urothelial CarcinomaRefractory Bladder Urothelial Carcinoma+3 more

Estimated

~$10 – $6,250

Mayo ClinicNCT07087860